Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility
Tuomo Mantere(Oulu University Hospital), Katri Pylkäs(University of Oulu), Arja Jukkola‐Vuorinen(University of Oulu), Anne Kallioniemi(University of California, San Francisco), Päivi Auvinen(University of Eastern Finland), Anna Nurmi(University of Helsinki), Riitta Hanhisalo(NordLab), Robert Winqvist(Oulu University Hospital), Kristiina Aittomäki(Helsinki University Hospital), Sini Lehto(University of Helsinki), Pentti Nieminen(University of Oulu), Heli Nevanlinna(University of Helsinki), Carl Blomqvist(University of Helsinki), Anna Tervasmäki(NordLab), Anders Kvist(Lund University), Johanna Schleutker(University of Turku), Maria Tengström(Kuopio University Hospital), Roger A. Greenberg(Penn Center for AIDS Research), Jaana M. Hartikainen(University of Eastern Finland), Saila Kauppila(University of Helsinki), Mervi Grip(University of Oulu), Åke Borg(Lund University), Maija Suvanto(University of Helsinki), Jiang-bo Tang(Cancer Research Institute), Katrin Rapakko(University of Oulu)
Cited by 37
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k